RNA Interference News and Research

RSS

Genes associated with autism interact to modulate variable symptoms of disease

Genes located in a large chromosomal aberration associated with autism interact with each other to modulate the variable symptoms of the disease, according to new research.

29 Jun 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

Researchers identify protein essential for eye lens development and clear vision

If you want to take clear photographs, you don't use sandpaper to clear a smudge from your camera's lens. Similarly, if you want to see clearly, the lens of your eye has to be free of obstruction.

21 May 2018

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.

14 May 2018

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and is planning to advance a pipeline of investigational RNAi therapeutics into clinical development.

8 May 2018

New eye drop may be potentially effective in treating seasonal eye allergies

A recent study shows that a new eye drop may be a potentially effective treatment for seasonal eye allergies, a condition affecting millions of people worldwide.

4 May 2018

Sylentis presents clinical study results of new treatment for dry eye syndrome

Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III "Helix" clinical trial.

3 May 2018

New insight may allow researchers to design drugs that improve immune responses to vaccines

Memory T cells are a critical element of our immune system's historical archive. To prevent repeat infections, these cells retain a record of germs they've fought before.

19 Apr 2018

Discovery of new ALS gene points to cytoskeleton as potential target for drug development

An international team of researchers led by John Landers, PhD, at UMass Medical School, and Bryan Traynor, MD, PhD, at the National Institute on Aging at the National Institutes of Health, has identified KIF5A as a new gene associated with the development of amyotrophic lateral sclerosis.

21 Mar 2018

Researchers use RNA nanotechnology to program exosomes for delivering effective cancer therapies

A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA specifically to cancer cells.

13 Dec 2017

Researchers discover potential regulator essential for killer T cells to reside in tumors

Researchers report the discovery that a protein called "Runx3" programs killer T cells to establish residence in tumors and infection sites.

11 Dec 2017

Texas Biomedical Research Institute tests promising new treatment for HBV infection

Research at the Southwest National Primate Research Center on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

7 Nov 2017

KU Leuven researchers find that humans have lost ancient defense mechanism to combat viruses

Insects and plants have an important ancient defense mechanism that helps them to fight viruses. This is encoded in their DNA. Scientists have long assumed that vertebrates - including humans - also had this same mechanism. But researchers at KU Leuven, Belgium, have found that vertebrates lost this particular asset in the course of their evolution.

15 Sep 2017

Researchers identify gene that could play role in energy requirements of liver cancer cells

A little-studied gene may explain how some liver cancer cells obtain the nutrition they need to proliferate, according to new research from the University of Maryland.

10 Aug 2017

MGH researchers identify novel mechanism behind resistance to angiogenesis inhibitors

A Massachusetts General Hospital research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels.

14 Jul 2017

Genetic manipulation of exosomes may offer new therapeutic approach to treating pancreatic cancer

Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.

8 Jun 2017

Leti's New Deal project could revolutionize IBD therapies for great benefit of patients in the European Union

Leti, a technology research institute of CEA Tech, today announced a European Union project to develop a nanotherapy targeting the molecules involved in inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis.

12 May 2017

Scientists develop novel technique to screen non-coding DNA of genome for diseases

Researchers have developed a method to swiftly screen the non-coding DNA of the human genome for links to diseases that are driven by changes in gene regulation.

4 Apr 2017

Single dose of siRNA molecule offers protection against heart attack and stroke in high-risk patients

Even a single dose of a specific ribonucleic acid molecule, known as a small interfering RNA (siRNA), offers patients at high risk of cardiovascular disease long-lasting protection against high LDL cholesterol - one of the main risk factors for heart attack and stroke.

30 Mar 2017

New gene-silencing drugs cut cholesterol levels by half in early research

The first in a new class of gene-silencing drugs, known as inclisiran, has been shown to halve cholesterol levels in patients at risk of cardiovascular disease.

21 Mar 2017